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Available online 10 September 2016Chemotherapy-induced neurotoxicity can reduce the quality of life of patients by affecting their intelligence,
senses and mobility. Ten percent of safety-related late-stage clinical failures are due to neurological side effects.
Animal models are poor in predicting human neurotoxicity due to interspecies differences and most in vitro as-
says cannot distinguish neurotoxicity from general cytotoxicity for chemotherapeutics.
Wedeveloped in vitro assays capable of quantifying thepaediatric neurotoxic potential for cytotoxic drugs.Mixed
cultures of human fetal brain cells were differentiated in monolayers and as 3D-neurospheres in the presence of
non-neurotoxic chemotherapeutics (etoposide, teniposide) or neurotoxicants (methylmercury). The cytotoxic
potency towards dividing progenitors versus differentiated neurons and astrocytes was compared using: (1) im-
munohistochemistry staining and cell counts in monolayers; (2) through quantitative Western blots in
neurospheres; and (3) neurospheremigration assays. Etoposide and teniposide,were 5–10 times less toxic to dif-
ferentiated neurons compared to the mix of all cells in monolayer cultures. In contrast, the neurotoxicant meth-
ylmercury did not exhibit selectivity and killed all cellswith the samepotency. In 3Dneurospheres, etoposide and
teniposide were 24 to 10 times less active against neurons compared to all cells. These assays can be used
prioritise drugs for local drug delivery to brain tumours.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Neural stem cell
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In vitro neurotoxicity assay
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Repurposing chemotherapeutics1. Introduction
Neurotoxicity is a serious side-effect which can result in diminished
cognitive, sensory and motor functions in patients. Neurotoxicity has
grave implications for the patients' quality of life; it affects employabil-
ity, family life and independence. More than 30% of drug safety failures
in phase I and II clinical trials are due to neurologic side effects (Redfern
et al., 2010; Cook et al., 2014). In addition 7%–10% of the discontinued
drugs in late clinical trials and marketed drugs are withdrawn due to
neurotoxicity (Guengerich, 2011; Siramshetty et al., 2016). These late-
stage failures can be very expensive, affect thousands of patients and
are among the top reasons for the increasing costs of bringing newmed-
icines to market (Tsaioun et al., 2009).
While the neurotoxic side-effects of anti-cancer chemotherapy are
often overlooked, they can have long-lasting impact on the quality ofCancer and Stem Cells, Queen's
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. This is an open access article undersurvivorship for patients. For example, adolescent patients treated
with vincristine develop painful peripheral neuropathy that can last
for years (Bukowinski et al., 2015) and accidental administration of
the drug in the cerebrospinal ﬂuid is fatal (Alcaraz et al., 2002). Periph-
eral neuropathy is a potentially dose-limiting side-effect of taxanes,
platinates, bortezomib and thalidomide (Miltenburg & Boogerd,
2014). Although the blood-brain barrier protects the brain from most
of the above chemotherapeutics, drugs which can distribute to the cen-
tral nervous system decrease cognitive functions (e.g. 5-ﬂuorouracil
(Wefel et al., 2010)), precipitate encephalopathy (methotrexate
(Shuper et al., 2000)), and damage the cerebellum (cytarabine
(Lazarus et al., 1981)).
Neurotoxicity is evenmore important in the context of brain cancer,
where drugs need to distribute to the central nervous system (CNS), ei-
ther through the blood-brain barrier or via local delivery routes. Despite
toxicities, some neurotoxic drugs are used in local intra-cerebrospinal
ﬂuid regimens to prevent and eliminate leptomeningeal metastases
(Matloub et al., 2006; Chamberlain, 2012). Conroy et al. (2010) have
reviewed the literature in order to identify chemotherapeutics with
lower potential for neurotoxicity, which can be repurposed for local
intra-cerebrospinal ﬂuid therapy in children. The main problem they
have identiﬁed is the lack of data for the neurotoxic effects for a largethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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drugs for local CNS therapy would require testing a large panel of cyto-
toxic drugs for their ability to cause neurological damage and contrast-
ing that with the exposures necessary to eliminate tumours. In this
respect, it is vital to develop methods to quickly identify and prioritise
anticancer drugs without neurotoxic effects. The patient population
most likely to beneﬁt from local chemotherapy are children under
three, in whom radiotherapy is contraindicated due to severe
neurotoxicity.
The Organisation for Economic Co-operation and Development, the
US Food and Drug Agency and the European Medicines Agency rely
solely on in vivo data for neurotoxicity testing (OECD, 1997; OECD,
2007). However, animal models are poor in predicting neurotoxicity,
and miss between 30 and 45% of drugs with known neurotoxic side ef-
fects (Olson et al., 2000). These rodent studies cost €300,000 per com-
pound (Agarwal & Rice, 1997; Jenkinson, 2012; Knight & Rovida,
2014), use either 80 adult animals for neurotoxicity (OECD, 1997) or
80 litters (1000 pups) (OECD, 2007) for developmental neurotoxicity,
and take from one month to a year to complete.
In contrast to animal studies, in vitromodels for neurotoxicity testing
offer higher throughput and the advantage of using human cells. Cell
culture systems in 96- and 384-well plates allow for rapid testing of
large sets of compounds at a range of doses. Although the cells are cul-
tured in an artiﬁcial environment, using human tissue eliminates the
risk of interspecies differences which plague animal studies (Leist &
Hartung, 2013; Abbott et al., 1999; Singh& Ferrara, 2012). The increased
throughput and the ability to correctly classify neurotoxic compounds
have been demonstrated for a number of rodent tissue-based in vitro
models (Zurich et al., 2013; Hayess et al., 2013). However, recent studies
have shown important interspecies differences in chemical and drug
neurotoxicity towards rodents and humans (Baumann et al., 2015).
Therefore future in vitro models would need to be based on human
tissue in order to model human toxicity and fully capitalise on the ad-
vantages of in vitro culture.
Detecting speciﬁc neurotoxic effects of cytotoxic drugs on the nor-
mal brain in vitro is challenging. The majority of cells in the brain are
not dividing and are well-differentiated. In this respect, using dividing
tumour (SH-SY5Y), myc-immortalised cell lines (LUHMES (Smirnova
et al., 2015), ReNCell (Hoffrogge et al., 2006), iPSC (Schwartz et al.,
2015)) or poorly differentiated progenitors (hESC, fetal brain (Ivanov
et al., 2014; Ivanov et al., 2015)) could lead to many false-positive sig-
nals for cytotoxic drugs. While all chemotherapy drugs would appear
neurotoxic for these cells, clinical data for drugs like topoisomerase II
poisons (etoposide and teniposide), nitrosoureas (carmustine and
lomustine), dactinomycin and temozolomide show no evidence of neu-
rotoxicity (Conroy et al., 2010). Although LUHMES and SH-SY5Y cells
can be differentiated to more mature phenotypes (Schildknecht et al.,
2009), the presence of oncogenes makes them unsuitable to serve as
normal controls in experiments comparing the response of tumour
and normal cells.
Our recent work on human fetal brain neurospheres (Ivanov et al.,
2014; Ivanov et al., 2015) showed that human neural progenitor cells
are sensitive to etoposide and hypothesized that this is due to their rel-
atively undifferentiated state. Similar results for the effects of chemo-
therapy on neural progenitors have been reported by Dietrich et al.
(2006). While fetal brain cells are poorly suited to model adult neuro-
toxicity, they can be differentiated to mimic the developing brain of
children under three, who will be most likely to receive local brain-
targeted chemotherapy. In this manuscript we have differentiated
human fetal brain progenitors by withdrawing mitogens in order to
study the effects of chemotherapy on differentiated cultures. In addition
we have contrasted the effects of topo II drugs (etoposide and
teniposide) to that of the classic neurotoxicant methylmercury (Ekino
et al., 2007; Counter & Buchanan, 2004; Castoldi et al., 2001).
We used three different experimental setups to distinguish between
neurotoxicity and cytotoxicity (Fig. 1). The ﬁrst set of experimentsexposed a monolayer of differentiating neural stem cells to different
concentrations of etoposide and teniposide for 6 days (Fig. 1A). At the
end, Resazurin (Alamar blue) reduction was used as a surrogate mea-
sure for viability for some plates, while the cells in other plates were
stained and counted for nuclei (DAPI positive), neurons (βIII-tubulin
positive cells) and astrocytes (GFAP positive cells). The objective was
to compare the general measures of cytotoxicity, such as metabolic cy-
totoxicity assays and total cell counts, to counting speciﬁc cell popula-
tions, such as neurons and astrocytes. Thus, general toxicity was
distinguished from astrocyte or glia-speciﬁc toxicity.
The second experimental setup was based on methods validated by
the European Centre for Validation of Alternative Methods (ECVAM)
(Zurich et al., 2013), but used human fetal cells and three protein end-
points instead of rat cells and mRNA quantiﬁcation. Levels of GAPDH
were used as a surrogate marker for the viability of all cells in culture,
while levels of βIII-tubulin and GFAP were used to quantify toxicity to-
wards neurons and glia respectively. The human fetal brain cells were
cultured with the drugs as neurospheres in uncoated plates for 6 days
(Fig. 1B). Due to the three-dimensional nature of the cultures, we
could not perform direct cell counts as in the previous setup, however
there was sufﬁcient amount of tissue to analyse protein levels by quan-
titative Western blot analysis.
The third experimental setup sought to explore the effect of topo-
isomerase inhibition on the migration potential of neural stem cells
(Supplementary Fig. 1) (Moors et al., 2007). The cells were cultured as
uniformly-sized neurospheres for 3 days, treated with the drugs for
24 h and then transferred into a coated plate to migrate for 48 h in the
presence of each drug. Upon activation, neural stem cells in the normal
brain need to be able tomigrate from their niches to different regions of
the brain in order differentiate, and maintain the steady state in the
brain (Pilz et al., 2002; Sanai et al., 2011; Stiles & Jernigan, 2010). This
experimental setup aimed to identify the levels of etoposide and
teniposide which impair the natural migration potential of neural
stem cells.
2. Materials and methods
2.1. Chemicals and reagents
Dulbecco's Modiﬁed Eagle Medium (DMEM), F12 Ham's Nutrient,
Hank's balanced Salt Solution (HBSS), Phosphate Buffer Saline (PBS),
Glutamine, Heparin, Accutase, poly-D-lysine (PDL), laminin, Resazurin,
Brilliant blue dye, Triton X, bovine serum albumin (BSA), Dimethyl
Sulfoxide (DMSO), and DAPI (4′,6-diamidino-2-phenylindole) were
purchased from Sigma-Aldrich (UK). N2, B27 supplements, basic Fibro-
blast Growth Factor (bFGF) and Epidermal Growth Factor (EGF) were
obtained from Invitrogen (Thermo Fisher Scientiﬁc, UK). Suspension
cell culture ﬂasks (non-treated, 25cm (Cook et al., 2014))were supplied
by PAA (GE Healthcare, Little Chalfont, UK), 48 well plates were obtain-
ed from Nunc (Thermo Fisher Scientiﬁc, UK), 96 well plates (Ultra Low
attachment) were purchased from Corning (Flintshire, UK). The list of
antibodies used in the experiments is given in Table 1.
2.2. Methods
2.2.1. Cell culture
Fetal human brain tissuewas received from the JointMRC/Wellcome
Trust (grant # 099175/Z/12/Z, Ethics committee approval 08/H0906/
21 + 5, Health Research authority NRES Committee North East - New-
castle & North Tyneside 1) Human Developmental Biology Resource
(www.hdbr.org). The tissue was rinsed, mechanically dissociated into
a single cell suspension and cultured in non-treated ﬂasks to form
stem cell enriched neurospheres (Uchida et al., 2000).
The Neural stem cell (NSC) deﬁned serum-free media was made
using DMEM/F12 (1:1), B27 (1:50), N2 (1:100), L-Glutamine (2 mM),
human epidermal growth factor (EGF, 20 ng/ml), basic ﬁbroblast
Fig. 1. Time course of the drug treatment protocols for monolayer (A), neurosphere (B) and migration (C) assays. A-human fetal brain cells were treated in differentiating conditions as
monolayers with drug for 6 days in poly-D-lysine and laminin coated plates. Resazurin metabolism, number of nuclei (DAPI) and cells staining for βIII-tubulin or GFAP were used to
compare general cytotoxic effects to lineage-speciﬁc toxicity. B-human fetal brain cells were cultured as neurospheres for 6 days and then the quantity of GAPDH, βIII-tubulin and
GFAP quantiﬁed using Western blotting. GAPDH was used as a surrogate for all cells, βIII-tubulin for neurons, GFAP-astrocytes.
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were subcultured for less than 25 passages as described by Ivanov et
al. (2015). NSC Differentiation media composition was the same NSC
media composition with the omission of EGF and FGF.
2.2.2. Differentiating monolayer cultures of fetal brain tissue
Differentiation of human fetal brain tissue-derived cells was per-
formed in poly-D-lysine (PDL) and laminin coated 48-well plates. The
plates were coated with PDL (5 μg/cm2, overnight at room tempera-
ture), washed with distilled water (three times) and coated with lami-
nin (2 μg/cm2, 2 h at 37 °C).
Human fetal neurospheres were dissociated to form a single-cell
suspension using Accutase (Ivanov et al., 2014) and were plated at
30,000 cells/well in NSC differentiation medium (500 μl) in 48-well
plates.Table 1
List of antibodies used in the Western blot and immunohistochemistry experiments.
Antibodies Dilution Sources Cat. no
Western blot primary
Mouse monoclonal anti-tubulin III antibody 1:2000 Abcam ab78078
Rabbit polyclonal anti-GFAP antibody 1:20,000 Abcam ab7260
Mouse monoclonal anti-GAPDH antibody 1:5000 Sigma G8795
Western blot secondary
Goat anti-mouse 1:30,000 Li-Cor
Odyssey
926-32211
Goat anti-rabbit 1:30,000 Li-Cor
Odyssey
926-68020
Immunohistochemistry primary
Mouse monoclonal anti-tubulin III antibody 1:500 Abcam ab7751
Rabbit polyclonal anti-GFAP antibody 1:800 Abcam ab7260
Immunohistochemistry secondary
Goat polyclonal anti-mouse IgG, Alexa Fluor 488 1:500 Abcam ab150113
Goat polyclonal anti-rabbit IgG, Alexa Fluor 555 1:500 Abcam ab1500982.2.3. Drug treatment
All compounds were added immediately after seeding the cell sus-
pension. Cells in untreated wells (controls) were suspended in 0.2%
DMSO solution. Etoposide and teniposidewere dispensed from separate
stock solutions (500× in DMSO) for each concentration (ﬁnal levels of
0.2% DMSO), in a set of six concentrations spaced in half-logarithmic
steps. Methylmercury chloride was dissolved in distilled water. There
were 6 technical replicates for each condition. The cells were incubated
in the differentiation medium for 6 days and all media solutions were
replaced every three days.
2.2.4. Resazurin metabolism-based viability assay
At the end of day 6, the medium was replaced with Resazurin solu-
tion (500 μl/well, 10 μg/ml, in HBSS), and the plate was left for 1 h at
37 °C in the incubator. Afterwards, ﬂuorescence was measured with
an excitation wavelength of 530 nm and emission 590 nm on a Galaxy
Fluostar plate reader.
2.2.5. Immunohistochemistry
The same drug treatment concentrations as in Section 2.2.3 were
used,with 2 technical replicates per condition. 20,000 cells were seeded
in each well in differentiation media (500 μl), incubated for 6 days with
onemedia change at day 3. At the end of day 6 themediumwas aspirat-
ed and the cells were ﬁxed in paraformaldehyde solution (4% wt/wt in
PBS, 15min). Combined blocking and permeabilizationwas done in Tri-
ton-X (0.25% vol/vol) and bovine serumalbumin (1%wt/wt) for 30min,
followed by washing with PBS (three times, 5 min each). Primary anti-
bodies anti-βIII-tubulin (1:500, TU-20 mouse monoclonal, Abcam
ab7751) and anti-GFAP (1:800, rabbit polyclonal, Abcam ab7260)
were added together overnight at 4 °C. On the next day, after washing
with PBS (three times, 5 min each), secondary antibodies (goat poly-
clonal anti-mouse, Alexa Fluor 488 ab150113 and anti-rabbit IgG,
Alexa Fluor 555 ab150098) were added in (1:500, 1 h). After a PBS
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phenylindole - DAPI (1:1000, 2 min), followed by a ﬁnal PBS wash (2
times). Wells were covered with glycerol mounting media (50:50 vol/
vol glycerol:PBS) containing 2.5% wt/vol DABCO (1, 4-diazabicyclo-
[2,2,2]-octane).2.2.6. Fluorescence microscopy
Imaging was performed on a Nikon Ti Eclipse inverted ﬂuorescence
microscope using 4× objective for image quantiﬁcation (Fig. 4) and im-
ages acquired at 20× for representative image illustrations (Fig. 3).
Table 2 lists theﬁlters used in theﬂuorescencemicroscopy experiments.2.2.7. Image analysis algorithms
All images were analysed using the 2016 version Fiji Distribution
(Schindelin et al., 2012) of ImageJ (Schindelin et al., 2015).
DAPI-stained nuclei images of all cells were thresholded using the
Otsu algorithm (Otsu, 1979). Overlapping nuclei were separated using
ImageJ's Watershed function and the number of particles with size be-
tween 10–1000 μm2 counted for each condition.
The algorithm for quantifying βIII-tubulin cells included the follow-
ing steps:manually set threshold to distinguish positive cells fromback-
ground, noise removal ﬁlter (Despeckle), a minimum ﬁlter (radius=2)
to remove neuronal processes,watershed step to separatemerging neu-
ronal bodies and an “Analyze particles” ﬁnal step to count cell-bodies,
30–2000 μm2 in size, with circularity greater than 0.3.
Astrocytes were counted by applying a manually set threshold to
hold to separate positive cells from background, noise removal ﬁlter
(Despeckle), a minimum ﬁlter (radius = 2) and counting all particles
with size from 50 to 10,000 μm2.2.2.8. Western blots
For the western blot experiments, 10,000 cells were seeded (NSC
differentiation media, 500 μl) in uncoated 48 well plates with 6 techni-
cal replicates per condition. Drug treatment was done for 6 days with
onemedium change at day 3. On day 6, themedia and the neurospheres
were transferred to a microcentrifuge tube and centrifuged
(13,000 RPM for 1 min). The supernatant was removed and the pellets
were washed twice with ice cold PBS. Protein content was quantiﬁed
and normalised using the Lowry assay and the western blot performed
according to Qureshi (Shaikh Qureshi, 2012).
The primary antibodies were diluted in 5% milk solution and the
dilutions were as follows: anti-tubulin III (mouse monoclonal anti-
body-Abcam ab78078) 1:2000, anti-GFAP (rabbit polyclonal antibody-
Abcam ab7260) 1:20,000, anti-GAPDH (mouse monoclonal antibody-
Sigma G8795) 1: 5000. Appropriate amounts of these antibodies were
used in sealed nylon bags to incubate the blots overnight in the refriger-
ator at 4 °C on a plate shaker. On the next day, the blotswerewashed by
TBST (50 mM Tris, 150 mM NaCl, 0.05% vol/vol Tween 20), three quick
washes, three 5 min washes and three 15 min washes to remove non-
speciﬁc binding. The secondary antibodies (IRDye 680LT goat anti-
mouse IgG (H + L) and IRDye 800CW goat anti-rabbit IgG (H + L))
were used in 1:30,000 dilution in 5% milk solution in TBST. The blots
were incubated with the secondary antibodies for 1 h on a plate shaker
at room temperature and then washed with TBST. The blots were
scanned using a Li-Cor Odyssey scanner and the intensity of the bands
quantiﬁed with Image studio 3.0.Table 2
Table of excitation and emission ﬁlters used in the ﬂuorescence microscopy experiments.
Nikon ﬁlter (name, stained entity) Excitation, nm Emission, nm
DAPI, DNA, nuclei 358 461
GFP, βIII-tubulin (neurons) 488 507
tdTomato, GFAP (astrocytes) 554 5812.2.9. Migration assay
The migration analysis was based on the technique described by
Moors et al. (2007). Brieﬂy, 10,000 cell per well were seeded in NSC
media (100 μl) in ultra-low attachment plates, centrifuged (300 RCF,
3 min) and left in the incubator to form one centrally placed
neurosphere per well. The neurospheres were cultured for 3 days until
they reached 350–400 μm diameter. At day 3 the neurospheres were
transferred to a 48 well plate (uncoated) and incubated for 24 h with
NSC differentiation media, 500 μl/well. At this point etoposide and
teniposide were added in a set of six concentrations spaced in half-log-
arithmic steps as in Section 2.2.3.
After 24 h incubation with the drugs, the neurospheres and drug so-
lutionswere transferred to a 48-well plate coated with PDL and laminin
(as described in Section 2.2.2). The neurospheres attached to the wells
within a few hours and individual cells started migrating outwards.
Photographswere taken at 0 h, 24 h and 48 h after plating for migration
(24, 48 and 72 h with the drugs respectively). The migration distance
was calculated as half of the difference between the diameter of the fur-
thestmigrating cells and the initial neurosphere diameter at t=0h. The
diameter of the migrating cells was calculated as the mean of two per-
pendicular diameters of the furthest cells migrating outwards.
2.2.10. Data analysis
Raw data were exported and analysed in MS Excel and Graphpad
Prism 6. Resazurin data were normalised relative to untreated control
(100%) and cell-free wells (0%). Western blot, cell migration data and
ﬂuorescently labelled cell counts were normalised to untreated controls
(100%) and 0 for (0%). Dose response curves were ﬁtted using the four-
parameter logistic equation in Prism, the top was constrained to 100%
and the bottom to the viability at the highest drug concentration. IC50
used are the inﬂection point of the dose-response curve, half-way be-
tween the untreated controls (100%) and the curve bottom (maximum
effect). Results are displayed asmean± SDunless stated otherwise. The
comparison of IC50 values was done using the logarithms of IC50
(logIC50) and the standard error of the IC50 from the non-linear regres-
sion analysis with the number of ﬁtted points as n. The values for
logIC50 for βIII-tubulin- and GFAP protein (Western blot experiments)
or positive cells (immunohistochemistry experiments) were compared
to the logIC50 for GAPDH or logIC50 for DAPI respectively using a one-
way ANOVA with Dunnett's correction for multiple comparisons and
the times differences betweenmeans plotted alongwith their 95%-con-
ﬁdence intervals (95%CIs).
3. Results
Both etoposide (Fig. 2A) and teniposide (Fig. 2B) elicited a dose-de-
pendent decrease in cell viability in differentiating monolayer cultures
of human fetal brain cells as measured by the Resazurin assay. While
the metabolic activity of the cultures was reduced down to 30%, at the
highest concentrations for both drugs, compared to untreated controls,
the IC50 for teniposide was 4 times lower than etoposide.
In a separate experiment the differentiating fetal brain cells were
treated with increasing concentrations of the neurotoxic methylmer-
cury, etoposide and teniposide (Fig. 3). In order to distinguish the cell-
lineage speciﬁc effects of the drugs all nuclei were stained with DAPI,
neurons were stained for βIII-tubulin, while GFAP was used to identify
astrocytes. In the untreated cultures βIII positive cells varied from 30
to 60%, while astrocytes were 10–40%. All tested compounds caused a
dose-dependent decrease in the numbers of cells as a whole, the num-
bers of neurons and astrocytes. While, neurons were killed at higher
concentrations compared to all cells in the etoposide and teniposide
treated groups, mercury was equally toxic to all neural tissue cells
(Fig. 3).
Dose-response curves for mercury, etoposide and teniposide were
plotted when the numbers for all cells, neurons and astrocytes were
quantiﬁed for each concentration and normalised to untreated controls.
Fig. 2.Metabolic activity of differentiating neural progenitors, exposed to etoposide and teniposide. Resazurin reduction assay measured the metabolic activity of differentiating neural
progenitors treated with increasing concentrations of etoposide (A) and teniposide (B) for 6 days. Metabolic activity is given as percentage compared to untreated control, error bars
are standard deviations for 3 independent experiments.
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with IC50 in the nanomolar range. In contrast, the IC50s of βIII-tubulin
expressing cells for etoposide and teniposide were 5 and 10 times
higher respectively, when compared to the IC50s for all cells in the
well (Fig. 4G). For both topoisomerase drugs, the difference in IC50s
for βIII-tubulin-positive cells was statistically signiﬁcant, while the dif-
ference for GFAP-positive ones was not (Fig. 4D and F).
In order to conﬁrm the results from themonolayer experiments, the
fetal brain cells were cultured in neurosphere conditions for 6 days in
the presence of etoposide or teniposide (Fig. 1B). The amount of
GAPDH, βIII-tubulin and GFAP were quantiﬁed by Western blot and
used as surrogate measures for the number of all cells, neurons and
astrocytes (Fig. 5A and C). Neurospheres were sensitive to etoposide
and teniposide in the micromolar range, similarly to monolayers
(Fig. 2). The levels ofβIII-tubulin andGFAP proteins decreased at higherFig. 3.Wide-ﬁeld ﬂuorescence images ofﬂuorescently labelled human fetal brain cells culturedu
andMercury (Hg, bottom). Nuclei are coloured blue (DAPI), βiii-tubulin expressing cells are sta
section (intermediate concentrations, around IC50) and right-section (high concentrations).concentration compared to GAPDH for both drugs. The etoposide IC50s
for βIII-tubulin and GFAP were 24 and 10 times higher than those for
GAPDH and the differences were statistically signiﬁcant using a one-
way ANOVA test with Dunnett's correction for multiple comparisons
(Fig. 5B and E). While the conﬁdence intervals for teniposide IC50
values were quite variable, spanning almost an order of magnitude,
the 9 times difference between βIII-tubulin and GAPDHwas statistically
signiﬁcant (Fig. 5D and E).
Both etoposide (Supplementary Fig. 2A) and teniposide (Supple-
mentary Fig. 2B) suppressed cell migration from fetal neurospheres in
a dose-dependent manner. At the highest concentrations etoposide-
treated neurospheres migrated to 27% of the distance compared to
untreated controls (Supplementary Fig. 2C). Teniposide treated
neurospheres migrated half the distance compared to controls. There
was little difference in the relative decrease of cell migration when thender differentiation conditions upon treatmentwith Etoposide (top), Teniposide (middle)
ined green and GFAP-positive cells are red. Left-hand images (untreated controls), middle
Fig. 4.Dose-response curves and comparison of IC50s for ﬂuorescently-labelled cells. A,C,E - dose response curves for Hg, etoposide and teniposide respectively; The dose response curves
for the number of nuclei of all cells are in blue, βiii-tubulin expressing cells (green) and GFAP-positive cells (purple). B,D,F differences between the logIC50s of βIII-tubulin expressing cells
(green) and all nuclei (DAPI) and between GFAP-positive cells (purple) and all nuclei (DAPI), error bars represent the 95%-conﬁdence intervals of the difference. G - table listing the IC50s
for all dose response curves.
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concentrations where both metabolism and cell viability would have
been affected and therefore need to be interpreted with caution.
4. Discussion
Metabolism-based assay measuring reduction of substrates (MTT,
MTS, Resazurin) or cellular ATP are widely utilised to measure cytotox-
icity in vitro (Ivanov et al., 2014; Vinci et al., 2012). Although they are
well-suited for homogenous monocultures, their utility for measuring
viability in mixed populations and primary tissues may be limited.
While these assays will reliably detect general cytotoxic effects, they
may miss subtle differences in the sensitivity of different populations.Etoposide and teniposide elicited a dose-dependent decrease in the
metabolic activity (Fig. 2) and numbers of cells (Fig. 4) in differentiating
monolayers of human fetal brain cells. However, the numbers of neu-
rons and astrocytes dropped at higher concentrations compared to all
cells in culture, which resulted in 5–10 fold higher IC50 values. This
indicates that although etoposide and teniposide are cytotoxic, their
neurotoxic potency is 5–10 times lower. In contrast to topoisomerase
drugs, the neurotoxicantmethylmercurywas toxic to all cells regardless
of differentiation status.
The immunohistochemistry results in 2D were supported by
Western blot data in 3D human fetal brain neurospheres cultured for
the same duration of time with etoposide and teniposide. There was
good agreement between the IC50 values for metabolic activity in
Fig. 5.Quantity of GAPDH, βIII-tubulin and GFAP proteins in human fetal neurospheres after 6-day treatmentwith etoposide and teniposide. A and C - dose-response curves for etoposide
(A) and teniposide (C) GAPDH (black triangle), GFAP (purple square) and βIII-tubulin (green circle) for etoposide (A) and teniposide (C); Results from three independent experiments,
error bars are standard deviations. B and D- times differences between the logIC50s for βIII-tubulin (green) and GAPDH and between GFAP-positive cells (purple) and GAPDH, error bars
represent the 95%-conﬁdence intervals of the times difference; E - summary table with IC50 values, conﬁdence intervals and the minimal quantity of protein at the highest drug
concentration compared to the untreated control.
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neurospheres. This is probably due to our setup of forming the
neurospheres in the presence of drug and thus eliminating drug-
neurosphere penetration issues. By using the quantity of GAPDH as a
surrogate for all cells in the neurospheres, βIII-tubulin for the neurons
and GFAP for the astrocytes we were able to detect differences in drug
sensitivity between the cell-lineages. While the quantity of GAPDH
quickly decreased at the lowest etoposide and teniposide concentra-
tions, βIII-tubulin protein levels, dropped at 9–24 times higher levels.
Similarly the IC50 for the astrocytic protein GFAP was 8 times higher
compared to the IC50 for metabolic activity and GAPDH level. While
these results may have been inﬂuenced by protein stability and turn-
over times, they are indicative of the resistance of differentiated cells
to the effects of cytotoxic drugs.
These differences are not only statistically different, but they also
have a practical clinical signiﬁcance. The results show that etoposide
and teniposide have a therapeutic window where they can be used in
brain tumours without severely affecting the normal differentiated
brain cells. The safe levels for etoposide were 0.3 μM (2D) to 3 μM
(3D) for etoposide and 50 nM (2D) to 500 nM (3D) for teniposide re-
spectively. In order to stand a chance in eliminating brain tumours at
safe drug levels, the IC50s for etoposide and teniposide in tumour cells
in vitro would need to be much lower than the concentrations above.
The identiﬁed therapeutic window for etoposide, can explain the drug's
lack of neurotoxic side effects when administered intrathecally in chil-
dren at therapeutic concentrations (van der Gaast et al., 1992; Slavc et
al., 2003; Fleischhack et al., 2001). It would also serve to explain dataindicating neurotoxicity in animal studies using high doses of the drug
(Savaraj et al., 1992).
Although neurons were less sensitive to etoposide in these experi-
ments, they were still eliminated at the higher concentrations of
etoposide. This highlights an important limitation of this study. Because
βIII-tubulin is expressed in early neuronal progenitors, the observed ef-
fects are consistent with developmental neurotoxicity. However, the
experimental setup does not answer the question whether topo II
drugs would be equally toxic to the differentiated and mature nervous
system of adults.
While βIII-tubulin expressing cells were shown to bemore resistant
to topoisomerase drugs, GFAP-expressing cells showed similar drug
sensitivity to the overall mix of cells. Although GFAP is regarded as a
marker for astrocytes, its δ-isoform is expressed in some populations
of neural stem cells (Middeldorp & Hol, 2011) and GFAP-positive cells
can divide more rapidly, compared to neurons. Therefore, selective cy-
totoxicity of topoisomerase poisons towards dividing cells may explain
the effects on GFAP-positive cells. These data imply that etoposide and
teniposide could exhibit toxicity towards dividing reactive astrocytes
if administered locally after surgery. However the GFAP-positive cells
in our experiments may be phenotypically different to the reactive as-
trocytes in the brains of brain tumour patients.
Interpreting the results of migration assays is often difﬁcult for che-
motherapy drugs affecting cell division and proliferation due to the syn-
ergism of suppressing proliferation and inhibiting migration. In our
case, the dose-dependent decrease inmigration occurred at doses sufﬁ-
cient to affect metabolism and cell viability indicating that the decrease
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etoposide and teniposide. The shorter drug incubation period (3 days)
versus (6 days) and adding the drugs after spheroid formation would
also contribute to the decreased effect. Nevertheless, the data suggests
that etoposide and teniposide do not inhibit migration at non-cytotoxic
concentrations.
5. Conclusions
This work has shown that general cytotoxicity can be distinguished
from developmental neurotoxicity in human fetal brain cultures by
quantifying protein markers for neurons (βIII-tubulin) and astrocytes
(GFAP). Quantiﬁcation of differentiation markers on the protein level
revealed 9–24 times increased resistance to topoisomerase drugs of
the differentiated cells in fetal brain cultures compared to the mix of
all cells. Moreover, while neurotoxic compounds, like mercury, killed
all cells in fetal brain cultures, etoposide and teniposide were 5–10
times less toxic to cells of the neuronal lineage. The methodology can
be used as a pre-screen to identify chemotherapy drugs with lower
chance of causing neurological toxicity in vitro.
Direct cell kill of neuronal and glial cells is only one mechanism
through which chemotherapy can cause neurotoxicity. More subtle
changes such as leukoencephalopathy or disturbance in network func-
tionwould need to be examined with other assay setups. Therefore this
combination of methods cannot be used as a stand-alone substitute of
animal experiments. It would be best suited as parf of a panel of assays
which would also encompass functional endpoints such as myelination
changes, and disturbance in electrical activity and network
communication.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tiv.2016.09.007.
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